Home
Resources
Publications
Comparative Assessment of budesonide-MMX and Mesalamine in Active, Mild-To-Moderate Ulcerative Colitis: A Systematic Review and Network Meta-Analysis

Comparative Assessment of budesonide-MMX and Mesalamine in Active, Mild-To-Moderate Ulcerative Colitis: A Systematic Review and Network Meta-Analysis

Stefanos Bonovas, Georgios K Nikolopoulos, Daniele Piovani, Marien González-Lorenzo, Katerina Pantavou, Theodore Lytras, Laurent Peyrin-Biroulet, Silvio Danese

Br J Clin Pharmacol. 2019 Oct;85(10):2244-2254.

PMID: 31269287

Abstract:

Aims:
The comparative efficacy, safety and tolerability of budesonide-MMX and oral mesalamine in active, mild-to-moderate ulcerative colitis (UC) are unclear. We conducted a network meta-analysis to fill this evidence gap.
Methods:
We searched PubMed, Scopus, Embase, the Cochrane Library, clinical trial registries, regulatory agencies' websites and international conference proceedings, up to July 2018, to identify randomized controlled trials of adult patients with active, mild-to-moderate UC, comparing budesonide-MMX or mesalamine against placebo, or against each other, or different dosing strategies, for induction of remission. Two reviewers independently abstracted study data and outcomes, and assessed each trial's risk-of-bias.
Results:
We identified and synthesized evidence from 15 eligible trials including 4083 participants. Budesonide-MMX 9 mg/day and mesalamine >2.4 g/day had similar efficacy for induction of clinical and endoscopic remission (OR = 0.97; 0.59-1.60), both showing superiority over placebo (OR = 2.68; 1.75-4.10, and OR = 2.75; 1.94-3.90, respectively). Furthermore, mesalamine >2.4 g/day was more efficacious than mesalamine 1.6-2.4 g/day (odds ratio = 1.27; 1.03-1.56). Secondary analyses showed that mesalamine >2.4 g/day ranks at the top among comparator treatments regarding safety (serious adverse events; surface under the cumulative ranking area [SUCRA] 79.2%) and tolerability (treatment discontinuations or withdrawals from the study due to adverse events; SUCRA 96.7%). There was no evidence of inconsistency, while heterogeneity between studies and risk of publication bias were low.
Conclusion:
Budesonide-MMX and mesalamine >2.4 g/day had similar efficacy for induction of clinical and endoscopic remission in active, mild-to-moderate UC; however, mesalamine >2.4 g/day showed better tolerability. Further high-quality research is warranted.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP89576-B	Mesalamine		89-57-6	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: